Azitra Inc (AZTR)

Azitra, Inc.'s stock price declined significantly between November 2024 and November 2025. In November 2025, the company announced a $1.5 million private placement and addressed a false report regarding the sale of securities. Azitra announced Q3 2025 results and business updates in November 2025. In October 2025, the company announced positive preclinical data for its ATR-01 program and participated in a Dermatologic Rare Disease Panel at the Maxim Growth Summit. In August 2025, Azitra reported Q2 2025 results and business updates, including initial safety results and 50% enrollment in the Phase 1b clinical trial for ATR-12, acceptance of a poster detailing the Phase 1/2 clinical trial for ATR-04, and securing an equity line of credit for up to $20 million with Alumni Capital LP. In May 2025, Q1 results included the acceptance of a poster detailing the ATR-04 Phase 1/2 clinical trial at ASCO 2025, the establishment of the $20 million equity line of credit with Alumni Capital LP, and the closing of two public offerings that raised a total of $2.2 million.

Demand for Azitra, Inc.'s products is not subject to typical consumer demand seasonality. Demand is driven by the prevalence of targeted diseases, clinical trial success, regulatory approvals, and market adoption. No information suggests seasonal fluctuations in demand for its pipeline products.

Azitra, Inc. is a clinical biopharmaceutical company focused on precision dermatology, utilizing a microbial library and AI to develop therapies. Their pipeline includes ATR-12 for Netherton syndrome (Phase Ib), ATR-04 for EGFRi rash in cancer patients (Phase 1/2, Fast Track designation), and ATR-01 for ichthyosis vulgaris (positive preclinical data in October 2025). Azitra also has a collaboration with Bayer.

Azitra, Inc. is headquartered in Branford, Connecticut, United States. Broader international geographic footprint information is not explicitly available.

Direct information detailing Azitra, Inc.'s brand reputation is not readily available. The company's stock performance and addressing a false report regarding the sale of securities could impact its reputation among investors. Clinical trial progress and positive preclinical data contribute to its scientific and clinical standing.

Azitra, Inc. has a mix of institutional and individual ownership. Institutional shareholders hold approximately 0.41% to 8.0% of the company's shares. Major institutional owners include Geode Capital Management, LLC, National Bank Of Canada /fi/, UBS Group AG, Alumni Capital Management LLC, Bayer Healthcare LLC, and Fidelity Concord Street Trust - Fidelity Extended Market Index Fund. Insiders hold a significant portion of Azitra's stock, including Aaron Gl Fletcher and Leslie W. Kreis.